Stephanie Mehlis to Dermatologic Agents
This is a "connection" page, showing publications Stephanie Mehlis has written about Dermatologic Agents.
Connection Strength
0.237
-
Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study. J Eur Acad Dermatol Venereol. 2017 Oct; 31(10):1693-1699.
Score: 0.143
-
Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011 Sep; 165(3):652-60.
Score: 0.094